Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00919711 | Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy | PHASE3 | COMPLETED | 870 | — | — | Sep 1, 2009 | Mar 5, 2012 | Jul 28, 2020 | - | — |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry
| Arm | Type | Description |
|---|---|---|
| Denosumab 60 mg | EXPERIMENTAL | - |
| Risedronate 150 mg QM | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Actonel® | DRUG | Oral Actonel® (Risedronate) in total a 150mg per month (one 75mg tablet to be taken on each of 2 consecutive days per month). |
| Denosumab | DRUG | Denosumab 60 mg, once every 6 months, Subcutaneous |
Inclusion Criteria: * Ambulatory, post menopausal women aged 55 years or older at screening. Have received their first prescription of daily or weekly alendronate therapy, for the treatment for post menopausal osteoporosis at least 1 month prior to screening. Use of raloxifene, calcitonin or hormon...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Precision BioSciences, Inc. | DTIL | 1 | NA | Undisclosed |
| SI-BONE, Inc. | SIBN | 1 | — | Undisclosed |